BioCentury | Dec 7, 2009
Company News

Incyte, Novartis deal

...and Phase II testing for advanced polycythemia vera and essential thrombocythemia. Incyte retains rights to topical INCB18424...
BioCentury | Nov 25, 2009
Top Story

Novartis in-licenses Incyte compounds

...Phase II testing to treat advanced polycythemia vera and essential thrombocythemia. Incyte retained rights to topical INCB18424...
BioCentury | Sep 28, 2009
Clinical News

INCB18424: Phase IIb data

...a double-blind Phase IIb trial in 200 patients showed that all 3 doses of once-daily topical INCB18424...
BioCentury | Sep 28, 2009
Analyst Picks & Changes

Analysts Picks & Changes

...Buy Russo raised his target to $12 from $11 after all three doses of once-daily topical INCB18424...
BioCentury | Sep 22, 2009
Clinical News

INCB18424 meets psoriasis endpoint

...double-blind, U.S. trial enrolled 200 patients who received vehicle control or 0.5%, 1.0% or 1.5% topical INCB18424...
BioCentury | Sep 22, 2008
Clinical News

INCB18424: Phase IIa data

...Phase IIa trial (Study 201) in 28 patients showed that 1.0% once-daily and 1.5% twice-daily topical INCB18424...
BioCentury | Jan 14, 2008
Clinical News

INCB18424: Phase IIa data

...Data from an ongoing, 4-week Phase IIa trial in patients with mild-to-moderate psoriasis showed that topical INCB18424...
BioCentury | Oct 1, 2007
Clinical News

INCB18424: Phase Ib/IIa data

...In a placebo-controlled, dose-escalation Phase Ib/IIa trial in 18 patients with mild to moderate psoriasis, topical INCB18424...
Items per page:
1 - 8 of 8